Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GR 138950

Known as: GR-138950, GR138950 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The actions of angiotensin II on type 1 (AT₁) and type 2 (AT₂) receptor subtypes are important for normal kidney development… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2008
Highly Cited
2008
PurposeThe aim of this study was to investigate and quantify drug movement to the brain via the neuro-olfactory system after… Expand
  • table I
  • figure 1
  • table II
  • table III
  • table IV
2007
2007
It has been shown that vasoconstrictive drugs such as ephedrine derivatives are able to decrease systemic absorption of drugs… Expand
2004
2004
Glucocorticoids increase blood pressure in utero, but the mechanisms responsible are unclear. This study investigated the… Expand
2000
2000
1 The effects of cortisol on blood pressure and the circulating components of the renin‐angiotensin system (RAS) were… Expand
1997
1997
The effects of maternal administration of either an angiotensin II type 1 (AT1) receptor antagonist (GR138950) or an angiotensin… Expand
1997
1997
The effect of blockade of the renin-angiotensin system on kidney function using non-peptide angiotensin AT1 receptor antagonists… Expand
1997
1997
1 The effect of systemic administration of the nitric oxide synthase inhibitor, NG‐nitro‐L‐arginine methyl ester (L‐NAME) on the… Expand
1995
1995
The antagonist activity of GR138950 (1-[[3-bromo-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5- benzofuranyl]methyl]-4… Expand
1994
1994
We have identified GR138950, a potent antagonist of the angiotensin II receptor with high oral bioavailability, as our second… Expand